Mechanisms involved in carcinogenesis of the breast

Breast Cancer: Prognosis, Treatment, and Prevention

Volumn , Issue , 2002, Pages 1-18

  Russo, José ^a   Russo, Irma H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72649085066     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (107)

1. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Hamalainen E. Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86: 1644-1645, 1994.
2. Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the “resting” human breast: Influence of parity, contraceptive pill, age and laterality. Br J Cancer 46: 376-382, 1982.
3. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway. Stimulation of adenylate cyclase and cAMP regulated gene transcription. Proc Natl Acad Sci USA 91: 8517-8521, 1994.
4. Ashburn SP, Han X, Liehr JG. Microsomal hydroxylation of 2- and 4-fluoroestradiol to catechol metabolites and their conversion to methyl ethers: Catechol estrogens as possible mediators of hormonal carcinogenesis. Mol Pharmacol 43: 534-541, 1993.
5. Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Lancet 2: 331-334, 1988.
6. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 15: 48-65, 1993.
7. Bradlow HL, Hershcopf J, Martucci C, Fishman J. 16a-Hydroxylation of estradiol-A possible risk marker for breast cancer. Ann NY Acad Sci 464: 138-151, 1986.
8. Brueggemeier RW, Katlic NE, Palmer CW Jr, Stevens JM. Catechol estrogen formation in MCF-7 culture and effects of bromoestrogen inhibitors. Mol Cell Endocrinol 64: 161-167, 1989.
9. Bunyagidj C, McLachlan JA. Catechol estrogen formation in mouse uterus. J Steroid Biochem 31: 795-801, 1988.
10. Calaf G, Alvarado ME, Bonney GE, Amfoh KK, Russo J. Influence of lobular development on breast epithelial cell proliferation and steroid hormone receptor content. Int J Oncol 7: 1285-1288, 1995.
11. Calaf G, Russo J. Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483-492, 1993.
12. Chivers C, Mant D, Pike MC. Cervical adenocarcinoma and oral contraceptives. Br Med J 295: 1446-1447, 1987.
13. Clarke RB, Howell A, Potter CS, Anderson E. Dissociation between steroid receptors expression and cell proliferation in the human breast. Cancer Res 57: 4987-4991, 1997a.
14. Clarke R, Dickson RB, Lippman ME. Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12: 1-23, 1992.
15. Clarke RB, Howell A, Anderson E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat 45: 121-183, 1997b.
16. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors a and ß form heterodimers on DNA. J Biol Chem 272: 19858-19862, 1997.
17. Creveling CR, Inoue K. Catechol-O-methyltransferase: Factors relating to the carcinogenic potential of catecholestrogens. Polycyc Aromat Comp 6: 253-259, 1994.
18. Cunningham MP. Giving life to numbers. CA 47: 3-4, 1997.
19. Dabelow A. Die Milchdruse. In: Bargmann W, ed. Handbuch der Mikroskopishen Anatomie des Menschen. Vol 3. Part 3: Berlin: Springer-Verlag, 1957, pp 277-489.
20. Dickson R, Russo J. Biochemical control of breast development. In: Harris JR, ed. Diseases of the Breast, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999, pp 15-31.
21. Dotzlaw H, Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-ß in human breast tumors. J Clin Endocrinol Metab 82: 2371-2374, 1997.
22. Dwivedy I, Devanesan P, Cremonesi P, Rogan E, Cavalieri E. Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem Res Toxicol 5: 828-833, 1992.
23. Edwards RG, Howles CM, Macnamee C. Clinical endocrinology of reproduction. In: Baulieu EE, Kelly PA, eds. Hormones: From Molecules to Disease. New York and London: Chapman & Hall, 1990, pp 457-476.
24. Ferguson DJP, Anderson TJ. Morphologic evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast. Br J Cancer 44: 177-181, 1981.
25. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 768: 91-100, 1995.
26. Going JJ, Anderson TJ, Battersby S. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130: 193-204, 1988.
27. Goodman HM, ed. Basic Medical Endocrinology. New York: Raven Press, 1994, pp 288-290.
28. Greenwald P, Barolom JJ, Nasca PC. Vaginal cancer after maternal treatment with synthetic estrogens. N Engl J Med 285: 390-392, 1971.
29. Habel LA, Stamford JL. Hormone receptors and breast cancer. Epidemiol Rev 15: 209-219, 1993.
30. Haslan LC, Coates RJ, Block G. Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology 4: 25-31, 1993.
31. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48: 246-253, 1988.
32. Herbst AL. Clear cell adenocarcinoma and current status of DES-exposed females. Cancer 48: 484-488, 1981.
33. Hu YF, Lau KM, Ho SM, Russo J. Increased expression of estrogen receptor P in chemically transformed human breast epithelial cells. Int J Oncol 12: 1225-1228, 1998.
34. Hu YF, Russo IH, Zalipsky U, Lynch HT, Russo J. Environmental chemical carcinogens induce transformation of breast epithelial cells from women with familial history of breast cancer. In Vitro Cell Dev Biol 33: 495-498, 1997.
35. Huff KK, Knabbe C, Lindsey R, Kaufman D, Bronzert D, Lippman ME, Dickson RB. Multihormonal regulation of insulin-like growth factor 1-related protein in MCF-7 human breast cancer cells. Mol Endocrinol 2: 200-208, 1988.
36. Huseby RA, Maloney TM, McGrath CM. Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells in vitro. Cancer Res 144: 2654-2659, 1987.
37. Jordan C. Tamoxifen: The herald of a new era of preventive therapeutics. J Natl Cancer Inst 89: 747-749, 1997.
38. Katzenellenbogen BS. Dynamics of steroid hormone receptor action. Annu Rev Physiol 42: 17-35, 1980.
39. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev 15: 36-47, 1993.
40. Khan S, Rogers MAM, Khurana KK, Meguid MM. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90: 37-41, 1998.
41. King RJB. Effects of steroid hormones and related compounds on gene transcription. Clin Endocrinol 36: 1-14, 1992.
42. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R. Evidence that transforming growth factor P is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987.
43. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and p. Endocrinology 138: 863-870, 1997.
44. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustaffsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930, 1996.
45. Kuiper GGJM, Gustafsson JA. The novel estrogen receptor-P subtype: Potential role in the cell-and promotor-specific actions of estrogens and anti-estrogens. FEBS Lett 410: 87-90, 1997.
46. Kumar V, Stack GS, Berry M, Jin JR, Chambon P. Functional domains of the human estrogen receptor. Cell 51: 941-951, 1987.
47. Laidlaw IJ, Clark RB, Howell A, Owen AWMC, Potten CS, Anderson E. Estrogen and progesterone stimulate proliferation of normal human breast tissue implanted in athymic nude mice. Endocrinology 136: 164-171, 1995.
48. Lau KM, Leav I, Ho SM. Rat estrogen receptor-a and -P, progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Nobel rats. Endocrinology 139: 424-429, 1998.
49. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as a marker of human mammary tumors. Proc Natl Acad Sci USA 93: 3294-3296, 1996.
50. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10: 382-393, 1986.
51. Malins DC, Holmes EH, Polissar NL, Gunselman SJ. The etiology of breast cancer: Characteristic alterations in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 71: 3036-3043, 1993.
52. Masters JRW, Drife JO, Scarisbrick JJ. Cyclic variations of DNA synthesis in human breast epithelium. J Natl Cancer Inst 58: 1263-1265, 1977.
53. Meyer JS. Cell proliferation in normal human breast ducts fibroadenomas and other duct hyperplasias measured by nuclear labeling with tritiated thymidine. Hum Pathol 8: 67-81, 1977.
54. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Corgnati A, Sperotto L, Recaldin E, Spag-nolli P, Manfrin E, Bonetti A, Nortilli R, Tomezzoli A, Pollini GP, Modena S, Cetto GL. Prognostic significance of estrogen receptors in 405 primary breast cancers: A comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 45: 241-249, 1997.
55. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst 65: 559-569, 1980.
56. Mosselman S, Polma J, Dijkema R. ER P: Identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996.
57. Nandi S, Guzman RC, Yang J. Hormones and mammary carcinogenesis in mice, rats and humans- A unifying hypothesis. Proc Natl Acad Sci USA 92: 3650-3657, 1995.
58. Nissen ED, Kent DR. Liver tumours and oral contraceptives. Obstet Gynecol 46: 460-467, 1975.
59. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human estrogen receptor P (hERP) and its heterodimerization with ER a in vivo and in vitro. Biochem Biophys Res Commun 243: 122-126, 1998.
60. Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S. Human estrogen receptor P binds DNA in a manner similar to and dimerizes with estrogen receptor a. J Biol Chem 272: 25832-25838, 1997.
61. Pappos TC, Gametahu B, Watson CS. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 9: 404-410, 1994.
62. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progesterone, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 15: 17-35, 1993.
63. Potten CS, Watson RJ, Williams GT. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58: 163-170, 1988.
64. Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104: 938-967, 1996a.
65. Russo IH, Russo J. Role of hormones in cancer initiation and progression. J Mam Gland Biol Neoplasia 3: 49-61, 1998b.
66. Russo J, Russo IH. The cellular basis of breast cancer susceptibility. Oncol Res 11: 169-178, 1999.
67. Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor a and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 53: 217-227, 1999.
68. Russo J, Barnabas N, Zhang PL, Adesina K. Molecular basis of breast cell transformation. Radiat Oncol Invest 3: 424-429, 1996.
69. Russo J, Calaf G, Russo IH. A critical approach to the malignant transformation of human breast epithelial cells. CRC Crit Rev Oncog 4: 403-417, 1993.
70. Russo J, Gusterson BA, Rogers A, Russo IH, Wellings SR, van Zwieten MJ. Biology of the disease. Comparative study of human and rat mammary tumorigenesis. Lab Invest 62: 244-278, 1990.
71. Russo J, Hu YF, Yang X, Russo IH. Molecular and cellular basis of breast cancer: Role of the estrogen receptor in carcinogenesis. J Natl Cancer Inst 27: 17-37, 2000.
72. Russo J, Reina D, Frederick J, Russo IH. Expression of phenotypical changes by human breast epithelial cells treated with carcinogens in vitro. Cancer Res 48: 2837-2857, 1988.
73. Russo J, Rivera R, Russo IH. Influence of age and parity on the development of the human breast. Breast Cancer Res Treat 23: 211-218, 1992.
74. Russo J, Romero AL, Russo IH. Architectural pattern of the normal and cancerous breast under the influence of parity. J Cancer Epidemiol Biomarker Prev 3: 219-224, 1994.
75. Russo J, Russo IH. Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res 40: 2677-2687, 1980.
76. Russo J, Russo IH. Development of human mammary gland. In: Neville MC, Daniel CW, eds. The Mammary Gland: Development, Regulation, and Function. New York: Plenum Publishing, 1987a, pp 67-93.
77. Russo J, Russo IH. Biology of disease. Biological and molecular bases of mammary carcinogenesis. Lab Invest 57: 112-137, 1987.
78. Russo J, Russo IH. Development pattern of human breast and susceptibility to carcinogenesis. Eur J Cancer Prev 2: 85-100, 1993.
79. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. J Cancer Epidemiol Biomarker Prev 3: 353-364, 1994.
80. Russo J, Russo IH. Estrogens and cell proliferation in the human breast. J Cardiovasc Pharmacol 28: 19-23, 1996b.
81. Russo J, Russo IH. Role of hormones in human breast development-The menopausal breast. In: Progress in the Management of Menopause. London: Parthenon, 1997a, pp 1-10.
82. Russo J, Russo IH. Development of the human breast. In: Knobil E, Neill JD, eds. Encyclopedia of Reproduction. Vol 3. New York: Academic Press, 1998, pp 71-80.
83. Russo J, Russo IH. Role of differentiation in the pathogenesis and prevention of breast cancer. Endocr Rel Cancer 4: 7-21, 1997b.
84. Russo J, Russo IH. Differentiation and breast cancer development. In: Heppner G, Bittar ED, eds. Advances in Oncobiology. Greenwich, CT: JAI Press, 1998a, pp 1-10.
85. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 2: 5-73, 1982.
86. Ryan DE, Thomas PE, Reik LM, Levin W. Purification, characterization and regulation of five rat hepatic microsomal cytochrome P-450 enzymes. Xenobiotica 12: 727-744, 1992.
87. Shaw RW. Adverse long term effects of oral contraceptives-A review. Br J Obstet Gynecol 94: 724-730, 1987.
88. Spink DC, Eugster H-P, Lincolin DW II, Schuetz JD, Schuetz EG, Johnson JA, Kaminsky LS, Gierthy JF. 17P-Estradiol hydroxylation catalyzed by human cytochrome P450 IA1-A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 37: 235-238, 1992.
89. Spink DC, Hayes CL, Young NR, Christou M, Sutter TR, Jefcoat CR, Gierthy JF. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells- Evidence for induction of a novel 17P-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol51: 251-258, 1994.
90. Tanner JM. The development of the reproductive system. In: Tanner JM, ed. Growth at Adolescence. Oxford: Blackwell Scientific, 1962, pp 28-39.
91. Tay LK, Russo J. Metabolism of 7,12-dimethylbenz(a)anthracene by rat mammary epithelial cells in culture. Carcinogenesis 4: 733-738, 1983.
92. Tay LK, Russo J. Formation and removal of 7,12-dimethylbenz(a)anthracene-nucleic acid adducts in rat mammary epithelial cells with different susceptibility to carcinogenesis. Carcinogenesis 2: 1327-1333, 1981.
93. Telang NT, Axelrod DM, Bradlow HL, Osborne MP. Metabolic biotransformation of estradiol in human mammary explant cultures. Ann NY Acad Sci 586: 70-78, 1990.
94. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen metabolite 16a-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84: 634-638, 1992.
95. Topper J, Freedman C. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev 60: 1049-1060, 1980.
96. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V. Cloning, chromosomal localization, functional analysis of the murine estrogen receptor p. Mol Endocrinol 11: 353-365, 1997.
97. Tsai MJ, O’Malley BW. Molecular mechanisms of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486, 1994.
98. Tsutsui T, Barrett JC. Neoplastic transformation of cultured mammalian cells by estrogens and estrogen-like chemicals. Environ Health Perspect 105: 619-624, 1997.
99. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R. Expression of ERP in breast cancer cells: Does it play an important role? Proc Am Assoc Cancer Res 38: 297, 1997.
100. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R. Expression of estrogen receptor P messenger RNA variant in human breast cancer. Cancer Res 58: 210-214, 1998.
101. Vorherr H. Development of the female breast. In: Vorherr H, ed. The Breast: Morphology, Physiology and Lactation. New York: Academic Press, 1974, pp 1-18.
102. Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A, Muramatsu M. Agonistic effect of tamoxifen is dependent on cell type, ERE-promotor context, estrogen receptor subtype: Receptors a and p. Biochem Biophys Res Commun 236: 140-145, 1997.
103. Weisz J, Bui QD, Roy D, Liehr JG. Elevated 4-hydroxylation of estradiol by hamster kidney micro-somes: A potential pathway of metabolic activation of estrogens. Endocrinology 131: 655-661, 1992.
104. Wellings SR, Jensen MM, Marcum RG. An atlas of sub-gross pathology of the human breast with special reference to possible pre-cancerous lesions. J Natl Cancer Inst 55: 231-275, 1975.
105. Wilson NM, Chrisou M, Turner CR, Wrighton SA, Jefcoate CR. Binding and metabolism of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene by seven purified forms of cytochrome P-450. Carcinogenesis 5: 1475-1483, 1984.
106. Yan Z-J, Roy D. Mutations in DNA polymerase P mRNA of stilbene estrogen-induced kidney tumors in Syrian hamster. Biochem Mol Biol Int 37: 175-183, 1995.
107. Zhu BT, Liehr JG. Quercetin increases the severity of estradiol-induced tumorigenesis in hamster kidney. Toxicol Appl Pharmacol 125: 149-158, 1994.